Transcript: FDA commissioner Dr. Marty Makary on "Face the Nation with Margaret Brennan," June 1, 2025
The following is the transcript of an interview with FDA commissioner Dr. Marty Makary that aired on "Face the Nation with Margaret Brennan" on June 1, 2025.
MARGARET BRENNAN: Welcome back to Face the Nation. We're joined now by FDA Commissioner Dr. Marty Makary. Good morning.
FDA COMMISSIONER DR. MARTY MAKARY: Good morning.
MARGARET BRENNAN: Good to have you here in person.
DR. MAKARY: Good to be here.
MARGARET BRENNAN: So I want to get through a lot here, but one of the things we've noticed is this new COVID variant that seems to be circulating in Asia. I believe it's NB.1.8.1. It's a variant under monitoring. What do we need to know?
DR. MAKARY: Yeah so this appears to be a subvariant of JN.1, which has been the dominant strain so it's believed that there is cross-immunity protection. The COVID- COVID virus is going to continue to mutate, and it's behaving like a common cold virus. It's now going to become the fifth coronavirus that's seasonal, that causes about 25% of the cases of the common cold.
MARGARET BRENNAN: So you're thinking of it as like a flu-type variant, just a normal fluctuation.
DR. MAKARY: The flu mutates about 34 times more frequently than COVID. The COVID variant mutation rate appears to be a little more stable, but the international bodies that have provided some guidance on which strain to target, have suggested that either JN.1 or any of these subvariants would be reasonable strains to target.
MARGARET BRENNAN: So you don't seem overly concerned about that. I want to get now into some of the recommendations that have been very specific this week from the CDC and you with the HHS Secretary in this video announcement on Tuesday where Secretary Kennedy said the CDC was removing the COVID vaccine for healthy children and healthy pregnant women from its recommended immunization schedule. He then had a memo to the CDC rescinding recommendations for kids' vaccines, saying the known risks do not outweigh the benefits. Then late Thursday, the CDC said quote "shared clinical decision-making," which I think is just talking to your doctor should determine whether kids get vaccinated. Can you clearly state what the policy is? Because this is confusing.
DR. MAKARY: Yeah, we believe the recommendation should be with a patient and their doctor. So we're going to get away from these blanket recommendations in healthy, young Americans because we don't want to see--
MARGARET BRENNAN: For all vaccines?
DR. MAKARY: We don't- well on the COVID vaccine schedule, we don't want to see kids kicked out of school because a 12-year-old girl is not getting her fifth COVID booster shot. We don't see the data there to support a young, healthy child getting a repeat, infinite, annual COVID vaccine. There's a theory that we should sort of blindly approve the new COVID boosters in young, healthy kids every year in perpetuity, and a young girl born today should get 80 COVID mRNA shots, or other COVID shots in her average lifespan. We're saying that's a theory, and we'd like to check in and get some randomized, controlled data. It's been about four years since the original randomized trials, so we'd like an evidence based approach. Dr. Prasad and I published this in the New England Journal of Medicine last week, and we're basically saying we'd like to bring some confidence back to the public around this repeat booster strategy theory, because--
MARGARET BRENNAN: Your statement was not about repeat boosters. It says the vaccine is not recommended for pregnant women, the vaccine is not recommended for healthy children. That's different than annual boosters.
DR. MAKARY: Yeah at this point we're dealing, you know, it is a booster strategy- people would be getting the updated shot. So whether or not a young, healthy--
(CROSSTALK)
MARGARET BRENNAN: But what about kids who haven't gotten a shot?
DR. MAKARY: So we'd like to see the data. We'd love to see that- that data. It doesn't exist.
MARGARET BRENNAN: No, no, no, but on a practical level, for a parent at home, hearing you, trying to make sense here.
DR. MAKARY: Yeah. We're saying, take it back to your doctor.
MARGARET BRENNAN: Their child has not been vaccinated. Are you recommending that their first encounter with COVID be an actual infection?
(END CROSSTALK)
DR. MAKARY: We're not going to push the COVID shot in young, healthy kids without any clinical trial data supporting it. That is a decision between a parent and their doctor. And just so, I don't know if you know the statistics, but 80 for 88% of American kids, their parents, have said no to the COVID shot last season. So America, the vast majority Americans, are saying no. Maybe they want to see some clinical data as well. Maybe they have concerns about the safety--
(CROSSTALK)
MARGARET BRENNAN: I don't want to crowdsource my health guidance. I want a clear thing--
DR. MAKARY: The worst thing you--
MARGARET BRENNAN: --I wouldn't go with popularity--
DR. MAKARY: The worst thing--
MARGARET BRENNAN: --I'm going with, as you're saying, data--
DR. MAKARY: --Yeah so let's see the data.
(END CROSSTALK)
MARGARET BRENNAN: Okay. So the CDC data said 41% of children aged six months to 17 years hospitalized with COVID between 2022 and 2024 did not have a known underlying condition. In other words, they looked healthy--
DR. MAKARY: So--
MARGARET BRENNAN: --and COVID was serious for them.
DR. MAKARY: So first of all, we know the CDC data is contaminated with a lot of false positives from incidental positive COVID tests with routine testing of every kid that walks in the hospital--
MARGARET BRENNAN: You don't trust the CDC data?
DR. MAKARY: --When I go to the ICU, when I walk to the P- the we know, We know that data, historically under the Biden administration, did not distinguish being sick from COVID or an incidental positive COVID test. When you go to an ICU in America and you ask, how many people are in the ICU that are healthy, that are sick with COVID, the answer I get again and again is, we haven't seen that in a year or years. And so the worst thing you can do in public health is to put out an absolute universal recommendation in young, healthy kids. And the vast majority of Americans are saying, no, we want to see some data. And you say, Forget about the data. Just get it anyway.
MARGARET BRENNAN: Okay, so on data and transparency for decades, since 1964 it was the Advisory Committee on Immunization Practices, ACIP that went through this panel recommendation. People watched these things during COVID. The report was then handed up. It offered debate, it offered transparency, and it offered data points that people could refer back to. Why did you bypass all of this and just come down with a decision before the panel could meet and meet that data?
DR. MAKARY: That panel has been a kangaroo court where they just rubber stamp every single vaccine put in front of them. If you look at the minutes of the report from, they even say we were- generally want to move towards a risk stratified approach.
MARGARET BRENNAN: So why not let them do that in June?
DR. MAKARY: So in the meantime, we don't want an absolute recommendation for healthy kids to get it. They can do it, and that committee-committee will meet and make recommendations. But you look at the minutes of the last couple of years, they say we want a simple message for everybody, just so they can understand it. It was not a data based conversation. It was a conversation based on marketing and ease and and I've written an article titled "Why the people don't trust the CDC," and it's in part from that blanket strategy–
MARGARET BRENNAN: You're telling them not to right now. You just said don't trust the CDC.
DR. MAKARY: We're saying it's going to be between a doctor and a patient until that committee meets or more experts weigh in, or we get some clinical data. If there's zero clinical data, you're opining. I mean, you're just, it's a theory, and so we don't want to put out an absolute recommendation for kids with no clinical data at this point.
MARGARET BRENNAN: So you made this pronouncement as well on pregnant women. There is data. Researchers in the UK analyzed a series of 67 studies, which included 1.8 million women, and the journal BMJ Global Health published it. People can Google it at home, and it says the COVID vaccine in pregnant women is highly effective in reducing the odds of maternal SARS-CoV-2 infection, hospital admission and improves pregnancy outcomes with no serious safety concerns. This is data that shows that it is recommended or could be advised, for pregnant women to take this vaccine. Why do you find otherwise?
DR. MAKARY: There's no randomized control trial. That's the gold standard. Those 67 studies are mixed. The data in pregnant women is different for healthy versus women with a comorbid condition. So it's a very mixed bag. So we're saying your obstetrician, your primary care doctor, and the pregnant woman should together decide whether or not to get it. 12% of pregnant women last year got the COVID shot. So people have serious concerns, and it's probably because they want to see a randomized trial data, the randomized trial of pregnant women–
MARGARET BRENNAN: But in the meantime, the world moves on, and you published in the New England Journal of Medicine on May 20. In that report, you referenced, you listed pregnancy as an underlying medical condition that increases a person's risk for severe COVID. You said that. So then seven days later, you joined in this video announcement saying you should drop the recommendation for the COVID vaccine in healthy pregnant women. So what changed in the seven days?
DR. MAKARY: In the New England Journal medicine, we simply list what the f- what the CDC has traditionally defined as high risk, and we're just saying, decide with your doctor. We're not saying the other–
MARGARET BRENNAN: But doctors want data and information as well from you–
DR. MAKARY: and the randomized trial– so here's the data on pregnant women. A randomized control trial was set up, and it was closed without any explanation. We wanted to see that trial complete so women can have information that in a randomized control trial, which is the gold standard, this is what the data shows. We don't have those data.
MARGARET BRENNAN: All right. It is still unclear what pregnant women now should do until they get the data that you say--
DR. MAKARY: I'd say talk to their doctor.
MARGARET BRENNAN: When do they get the data you're promising? All these controlled studies.
DR. MAKARY: In the absence of data, they should talk to their doctor--
MARGARET BRENNAN: So no date?
DR. MAKARY: --and their doctor will use their best wisdom and judgment.
MARGARET BRENNAN: FDA Commissioner, thank you for trying to help clear this up.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
11 minutes ago
- Yahoo
Diet containing foods with this key component can lead to longer life, study finds
A diet containing daily servings of tea, berries, apples, oranges or grapes may lower the risk of early death and promote longevity. A new study published in the journal Nature Food concludes that people who consume a diverse range of foods rich in flavonoid molecules may have a lower risk of developing chronic health conditions and a higher potential to live longer. Consuming flavonoid food sources in the form of tea, berries, dark chocolate, and apples can prevent the development of conditions like type 2 diabetes, cancer and heart and neurological diseases, scientists, including from Queen's University Belfast, say. 'We have known for some time that higher intakes of dietary flavonoids, powerful bioactives naturally present in many foods and drinks, can reduce the risk of developing heart disease, type 2 diabetes as well as neurological conditions like Parkinson's,' study co-author Aedín Cassidy explains. 'We also know from lab data and clinical studies that different flavonoids work in different ways, some improve blood pressure, others help with cholesterol levels and decrease inflammation.' Flavonoid molecules are found abundantly in blueberries, strawberries, oranges, apples, grapes, and even tea, red wine and dark chocolate. 'Flavonoid intakes of around 500mg a day were associated with a 16 per cent lower risk of all-cause mortality as well as a 10 per cent lower risk of cardiovascular disease, type 2 diabetes, and respiratory disease,' Benjamin Parmenter, another author of the study, says. 'That's roughly the amount of flavonoids that you would consume in two cups of tea.' The study, which involved tracking over 120,000 people aged 40 to 70 for over a decade, is the first of its kind to highlight a benefit to consuming a diverse range of flavonoids beyond simply consuming a high quantity. The findings indicate consuming a higher quantity and a wider diversity of flavonoid foods can lead to a greater reduction in ill health than just a single source. The research is in line with the popular belief that eating colourful foods is invaluable to maintaining good health. 'Eating fruits and vegetables in a variety of colours, including those rich in flavonoids, means that you are more likely to get the vitamins and nutrients you need to sustain a healthier lifestyle,' study author Tilman Kuhn says. 'The results provide a clear public health message,' says Dr Cassidy, 'suggesting that simple and achievable dietary swaps, like drinking more tea and eating more berries and apples, can help increase the variety and intake of flavonoid-rich foods, and potentially improve health in the long term.'
Yahoo
12 minutes ago
- Yahoo
5 things things we learned from Cancer Research UK's biggest report to-date
In the UK, more than 400,000 people are told they have cancer every year. Statistics suggest that nearly one in two of us will be diagnosed with the condition at some point in our lifetime, yet recent headlines suggest that the disease is evolving, with growing fears around a worrying uptick in early-onset cases. Now, Cancer Research UK has provided a clearer picture of how cancer is affecting us as a population, with a new report that analyses 50 years of UK-wide data on cancer mortality and cases. Called the Cancer in the UK Report 2025, the groundbreaking analysis reveals some fundamental facts about the average risk for developing cancer in the UK, and the probability of getting the all-clear. To help you easily digest its findings, here are five key things we learned from the report. Arguably the most impactful statistic from the report is that the number of people being diagnosed with cancer has risen by almost half in the UK. Despite improvements in prevention, detection, diagnosis and treatment over the past half a century, many more people are being diagnosed with cancer compared to 50 years ago. Cancer Research UK reports that incidence rates have sharply increased by almost half (47%) across Great Britain from 1973 to 2023, from around 413 cases per 100,000 people to around 607 cases per 100,000 people. In more reassuring news, the average person is more likely to beat cancer now than those who developed the disease back in the early 1970s – despite cases rising. The overall rate of people dying from cancer has fallen by around 22% over the past 50 years, with the report suggesting that three key things – research into improving screening programmes, tests and drugs – have helped to bring down death rates. The charity adds that policy action on smoking has also helped to shrink rates of lung cancer, a common type of cancer which is known to have a poorer survival rate. Perhaps surprisingly, given that smoking rates are at their lowest point on record, smoking remains the biggest cause of cancer in the UK and is responsible for around a fifth of all cancer deaths each year. To combat these figures, the government is currently working to pass a Tobacco and Vapes Bill, which aims to create the first smoke-free generation by banning the sale of tobacco to anyone born on or after 1 January 2009. If passed in Westminster, the bill will gradually phase out tobacco sales, effectively preventing future generations from starting smoking. With more people living with cancer than ever before, the number of daily diagnoses is on the rise too. The report estimates that nearly 1,100 new cases are diagnosed every day in the UK – that's around one every minute. The charity says that a growing and ageing population is partly behind this steady rise in new cancer cases, alongside rising obesity rates, which count for 5% of all cancer deaths in the UK. Cancer screening programmes are hardly the most fun things to attend, but the report highlights the importance of staying on top of routine appointments and common cancer symptoms. The three major types of cancer screening – bowel, breast and cervical – are estimated to save as many as 5,000 lives every year across the UK. Despite this, there's a mixed picture on uptake. Bowel screening participation has improved thanks to the rollout of the faecal immunochemical test (FIT), a simple stool test used to detect tiny amounts of blood in poo, but worryingly, breast screening participation is declining in England and Wales. Cervical screening participation is also declining, despite Jade Goody's high-profile battle with cervical cancer helping to reverse the downward trend in women going for screening in the mid 2010s. Speaking about the new report and its findings, Michelle Mitchell, Cancer Research UK's chief executive, said: "It's fantastic to see that thanks to research, cancer death rates have drastically reduced over the last 50 years, and survival has doubled. "However, there's more that can be done. This report highlights that over 460 people die from cancer every single day in the UK, and too many cases are diagnosed at a late stage. If we want to change that, we need bold action from the UK government." She adds: 'The upcoming National Cancer Plan for England must improve cancer survival, and transform cancer services. If this plan is done right, it could save countless lives across England and ensure people affected by cancer live longer, better lives.' Read more about cancer: The symptom that led to my breast cancer diagnosis (Yahoo Life UK, 5-min read) How to check for 4 types of cancer increasing in younger people (Yahoo Life UK, 5-min read) I saw breast cancer as a woman's illness and was too embarrassed to tell people I had it (Yahoo Life UK, 6-min read)
Yahoo
17 minutes ago
- Yahoo
Ohtani leads tributes as Japan's 'Mr. Pro Baseball' dies at 89
This picture taken on November 5, 1965 shows Shigeo Nagashima of the Yomiuri Giants (STR) Los Angeles Dodgers superstar Shohei Ohtani led the tributes to Japanese baseball legend Shigeo Nagashima following his death on Tuesday aged 89. Known as "Mr. Pro Baseball", Nagashima starred for Japan's most popular team, the Yomiuri Giants, winning nine straight Japan Series titles from 1965 to 1973. Advertisement He formed a lethal partnership with Sadaharu Oh, who holds the world record for hitting the most home runs, and the pair are credited with cementing baseball's status as Japan's favourite sport. Their batting exploits captivated a Japanese public enjoying new economic prosperity out of the ruins of World War II, with families tuning in to watch games on black and white televisions. Nagashima's outsized personality and easy charisma made him a popular public figure and symbol of a confident new Japan. He hit a dramatic walk-off home run to seal a win for the Giants in the first professional game ever attended by Japan's emperor in 1959. Advertisement "May your soul rest in peace," Ohtani wrote on Instagram to his 9.5 million followers, along with a picture of himself with Nagashima. Oh also paid tribute, telling reporters that he was "really shocked" to learn of his former team-mate's death. "I'm really disappointed that Mr. Nagashima, who shines brightly in the history of Japanese baseball, has departed after a long bout with illness," the 85-year-old Oh was quoted as saying by the Kyodo news agency. "He taught me a lot of things. I'm grateful to have been able to play with him." Nagashima retired in 1974 after a 17-year playing career during which he won the Central League batting title six times and was home run king twice. Advertisement He played in 2,186 games and hit 444 home runs. He also had two stints as the Giants' manager, winning two Japan Series titles over 15 seasons. Japan's Chief Cabinet Secretary said Nagashima was "a sunny person". "He left so many brilliant records in the world of professional baseball for many years and gave bright dreams and hopes to society as a national star," he said. amk-hih/pst
